SPECTRANETICS (NASDAQ:SPNC)
6.01
+0.16 (2.74%)
| SPECTRANETICS (NASDAQ:SPNC) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $5.85 | 52 Week High | $6.89 | ||
| Open | $5.81 | 52 Week Low | $1.91 | ||
| Day High | $6.01 | P/E | N/A | ||
| Day Low | $5.81 | EPS | $-0.27 | ||
| Volume | 54,705 | ||||
| More SPNC Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AMG | 1 | CEVA | 1 |
| EQR | 1 | JAH | 1 |
| OII | 1 | SUSQ | 1 |
| WLP | 1 | AVB | 1 |
| CSV | 1 | GSK | 1 |
| LOOP | 1 | Q | 1 |
Entities who have mentioned SPNC
- Citi | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Merrill Lynch | View Related Stories »
- Jefferies & Co | View Related Stories »
- Canaccord Adams | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- UBS | View Related Stories »
- Matrix USA | View Related Stories »
- New Home Sales | View Related Stories »
- Lazard | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- Crude Oil | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
View All Major News StreetInsider.com Major News for SPNC
- Spectranetics (SPNC) Posts Q3 Loss of $0.08
- Spectranetics (SPNC) Reports Q1 Loss of $0.09
- Spectranetics (SPNC) Reports Q4 Loss of $0.03, Misses by 1c
View All ReportsStreetInsider.com Reports on SPNC
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Spectranetics (SPNC) Posts Q3 Loss of $0.08
- Spectranetics (SPNC) Files 510(k) With FDA for the Treatment of In-Stent Restenosis in the Legs
- Canaccord Adams Upgrades Spectranetics (SPNC) to Buy
- Jefferies & Co Downgrades Spectranetics (SPNC) to Hold
View All Press ReleasesCompany Press Releases on SPNC
- Spectranetics to Present at the Canaccord Adams 3rd Annual Cardiovascular Conference on November 10
- Spectranetics Reports Third Quarter Revenue Up 7% to $28.8 Million
- Spectranetics to Hold 2009 Third Quarter Financial Results Conference Call on October 28
- Spectranetics Submits 510(k) Application to Food and Drug Administration Seeking Clearance for the Treatment of In-Stent Restenosis in the Legs
StreetInsider Reports on SPNC by Category
View All BlogsBlogs on SPNC
- Spectranetics Q3 2009 Earnings Call Transcript
- The Spectranetics Corporation Q1 2009 Earnings Call Transcript
- Spectranetics Q4 2008 Earnings Call Transcript
- The Spectranetics Corporation, Q3 2008 Earnings Call Transcript
- Analyst upgrades, downgrades and initiations: MET, COST, WAG, CAG...
Comments on SPNC
No comments are currently available.
